目的 探讨免疫增强型复合肠内营养制剂对脓毒血症肿瘤患者的临床疗效。方法 选择2018年6月至2020年7月重庆 市大足区人民医院重症监护室收治的符合入选标准的合并脓毒血症肿瘤患者，随机分为试验组和对照组，各30例。对照组给予 常规营养治疗，试验组在对照组的基础上加用富含免疫增强型复合肠内营养制剂治疗。并监测比较两组患者在3个时间点（0周、 1周、2周）白蛋白（ALB）、降钙素（PCT）、C反应蛋白（CRP）、序贯器官衰竭估计（SOFA）评分、D‐乳酸（D‐Lac）、二胺氧化酶（DAO） 和细菌内毒素的情况，监测两组发生肠功能障碍（腹泻、腹胀、胃潴留）的例数、肺部感染、重症监护室入住时间及死亡例数情况。 结果 两组患者的ALB、PCT、CRP、SOFA评分、肺部感染发生的例数、患者重症监护室入住时间及死亡例数、两组生存曲线之间差 异均无统计学意义（P>0.05)。肠功能监测指标（DAO、D‐Lac、内毒素）试验组较对照组下降幅度更大，差异有统计学意义（P<0.05)。 对照组肠功能障碍（腹泻、腹胀、胃潴留）发生的例数多于试验组，差异有统计学意义（P<0.05)；结论 早期肠内营养治疗均能改善 引起脓毒血症的肿瘤患者的营养及炎症反应状态，提高肿瘤患者的治疗疗效，其中免疫增强型复合肠内营养制剂治疗在改善肿 瘤患者的肠功能检测指标方面较显著，并一定程度减少了肠功能障碍并发症的发生。

Objective To investigate the clinical efficacy of immune enhanced enteral nutrition in patients with septic tumor. Methods From June 2018 to July 2020, the patients with sepsis in the intensive care unit of Chongqing Dazu District People′s Hospital were randomly divided into experimental group (n=30) and control group (n=30). The control group was given conventional nutrition treatment, and the experimental group was given immune enhanced compound enteral nutrition preparation on the basis of the control group. We also monitored and compared the serum albumin (ALB), calcitonin (PCT), C reactive protein (CRP), sequential organ failure assessment score (SOFA), D⁃lactate (D⁃Lac), diamine oxidase (DAO) and bacterial endotoxin in three groups of patients at three time points (0 weeks, 1 weeks, 2 weeks), and monitored intestinal function indexes of two groups of patients with intestinal dysfunction (diarrhea, abdominal distention, gastric retention). Pulmonary infection, ICU stay time and death cases. Results There were no significant differences in ALB, PCT, CRP, SOFA score, the number of cases of pulmonary infection, ICU stay time and death cases, and survival curve between the two groups (P>0.05). The indexes of intestinal function (DAO, D⁃Lac, endotoxin) in the experimental group decreased more significantly than those in the control group (P<0.05). The number of bowel dysfunction (diarrhea, abdominal distention, gastric retention) in the control group was more than that in the experimental group, with significant difference (P<0.05).Conclusion Early enteral nutrition therapy can improve the nutritional and inflammatory state of tumor patients with sepsis, and improve the therapeutic effect of tumor patients. Immune enhanced compound enteral nutrition therapy can improve the intestinal mucosal barrier function of tumor patients, and reduce the occurrence of intestinal dysfunction complications to a certain extent.